Clinical Trial Update: Neoadjuvant Paclitaxel Plus Epirubicin Versus Vinorelbine Plus Epirubicin in Breast Cancer With TEKT4 Variations [Phase 2]

View source ↗

Summary

Phase 2 trial comparing neoadjuvant paclitaxel plus epirubicin versus vinorelbine plus epirubicin in breast cancer with TEKT4 variations completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Epirubicin (epirubicin)
• PACLITAXEL (PACLITAXEL)
• Vinorelbine (Vinorelbine)

Snippet

Sponsor: Fudan University | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED